HIFU FOR
BONE METASTASES
MRgFUS (ExAblate Bone) delivers focused ultrasound to painful bone metastases — destroying the periosteal nerve fibres responsible for pain and ablating the tumour margin in a single outpatient session, with no radiation dose, no needle, and no recovery period.
analyticsAt a Glance
- check_circleFDA-approved (ExAblate 2100 Bone) for palliative treatment of painful bone metastases
- check_circlePhase III trial: 64% pain response rate at 3 months vs 20% for sham procedure
- check_circleNo radiation dose accumulated — can be used in patients who have exhausted radiotherapy options at the same site
- check_circleSingle outpatient session — most patients return to normal activity within 24–48 hours
Why HIFU for Bone Metastasis Pain Is Clinically Important
Bone metastases affect up to 70% of patients with advanced breast, prostate, lung, and kidney cancers — and bone pain is among the most common and debilitating symptoms in advanced oncology. External beam radiotherapy is the standard palliative option but has dose limits, requires repeated visits, and cannot be re-used at the same site once the maximum dose is reached. HIFU addresses all three constraints.
“For a patient who has already received 30 Gy to a spinal metastasis and whose pain has returned — re-irradiation carries genuine spinal cord risk. MRgFUS treats the same lesion without touching the radiation budget.”
Two Mechanisms of Bone Pain Relief
HIFU ablates bone metastasis pain through two distinct mechanisms: (1) periosteal nerve ablation — the thermal energy destroys the periosteal pain fibres at the cortical bone surface that generate the characteristic deep bone pain; (2) direct tumour cell destruction — reducing the tumour mass lowers local cytokine and prostaglandin release that sensitises pain fibres.
The No-Radiation Advantage
Cryoablation and HIFU both provide non-radiation bone metastasis treatment — but HIFU requires no probe insertion through the skin into the bone, making it applicable to superficial lesions and spine without the spinal nerve monitoring complexity required for cryoablation. For patients who have used their radiation allowance at a particular site, HIFU is currently the only non-invasive alternative.
Key Clinical Numbers
Data from the pivotal FDA registration trial and subsequent real-world series establish MRgFUS bone as a validated palliative intervention.
- 64%Pain response rate at 3 months (Phase III RCT)ExAblate Bone Phase III sham-controlled trial — compared to 20% sham response. Criterion: ≥2-point reduction in worst pain NRS score.
- 20%Complete pain relief rate at 3 monthsSubset of responders achieving zero pain at treated site — a particularly meaningful endpoint for bone pain palliation.
- 1 dayMedian time to pain onset after MRgFUSMost responders begin experiencing pain reduction within 24–72 hours of the procedure — substantially faster than the 4–6 week response window for radiotherapy.
- 0 GyRadiation dose delivered to patientMRgFUS uses acoustic energy — no ionising radiation whatsoever — allowing treatment of sites that have already received maximum radiotherapy doses.
Clinical Efficacy: Phase III Trial and Comparative Data
The FDA-registration Phase III sham-controlled trial and subsequent comparative data vs radiotherapy establish MRgFUS bone as a first-line palliative option.
ExAblate Bone Phase III — MRgFUS vs Sham (Hurwitz et al., JNCI 2014)
Source: Hurwitz MD et al., J Natl Cancer Inst. 2014;106(5):dju082. Primary endpoint: pain response at Day 90.
- Pain response: MRgFUS arm64%
- Pain response: Sham arm20%
- Complete pain response: MRgFUS20%
MRgFUS vs External Beam RT — Bone Pain (Prospective Comparative, Napoli et al.)
Source: Napoli A et al., Radiology. 2013;268(1):243–251. Prospective comparison in 39 patients.
- Pain response at 3 months: MRgFUS72%
- Pain response at 3 months: EBRT69%
- Complete response at 3 months: MRgFUS40%
- Complete response at 3 months: EBRT23%
Bone Metastasis Site Suitability for HIFU
Eligibility for HIFU bone treatment depends critically on the metastasis site — acoustic access, cortical integrity, and proximity to spinal cord or major nerves all affect suitability.
| Site | HIFU Suitability | Key Considerations |
|---|---|---|
| Appendicular skeleton (femur, humerus, tibia) | Excellent — acoustic access straightforward | Assess cortical integrity; large lytic lesions >50% cortex may need prophylactic fixation first |
| Pelvis / acetabulum | Good — requires careful planning | Weight-bearing implications; cementoplasty may be needed for structural lesions |
| Spine (vertebral body) | Feasible with MRgFUS thermometry monitoring | Spinal cord proximity — MR thermometry monitors cord temperature in real time during treatment; specialist centre required |
| Ribs | Good — relatively superficial | Pleural surface proximity; monitor for pleural effusion post-treatment |
| Skull | Transcranial MRgFUS for brain — separate indication | Standard bone MRgFUS not used for skull metastases |
| Sternum | Feasible — limited published data | Proximity to mediastinal structures; requires experienced operator and careful planning |
| Scapula / clavicle | Feasible | Brachial plexus proximity for scapular lesions — nerve monitoring strongly advised |
HIFU vs Radiotherapy vs Cryoablation for Bone Metastasis Pain
All three modalities provide durable bone pain palliation. Modality selection depends on prior treatment, lesion accessibility, and patient priorities.
HIFU (MRgFUS)
- No radiation dose — suitable after prior EBRTTreats lesions that have already received maximum radiation — the most important clinical niche for HIFU in bone pain palliation.
- No needle insertion — fully non-invasiveEliminates the fracture, bleeding, and infection risks associated with cryoprobe insertion through bone cortex.
- MR thermometry protects spinal cordReal-time temperature monitoring of the spinal canal distinguishes MRgFUS from all other bone metastasis ablation approaches for spinal disease.
- Faster pain relief than radiotherapyPain onset within 24–72 hours vs 4–6 weeks median response for EBRT — clinically important for patients in severe acute pain.
Radiotherapy / Cryoablation
- Radiotherapy: more widely available globallyEBRT requires no specialist HIFU centre — available at essentially every oncology centre worldwide with established palliative protocols and insurance coverage.
- Cryoablation: direct ice-ball margin confirmationIce-ball visualisation on CT provides immediate procedural endpoint assessment that HIFU ultrasound monitoring cannot fully replicate.
- Radiotherapy: effective for very large lesionsMulti-field EBRT can treat large volumes — entire vertebral segments or hemi-pelvic disease — that would require many HIFU sessions.
- Cryoablation: simultaneous tissue biopsyCore biopsy can be obtained in the same session as cryoablation — HIFU requires a separate procedure for histological diagnosis if not previously established.
More from the HIFU Therapy Resource Library
Continue exploring HIFU — from the technology platforms to other tumour site applications.
- HIFU Therapy — Complete Treatment Guide
- What Is HIFU? Non-Invasive Focused Ultrasound Explained
- HIFU for Pancreatic Cancer: Pain Relief and Local Control
- HIFU for Liver Cancer: HCC and Liver Metastases
- HIFU Technology Platforms: HAIFU, JC, and MRI-Guided Systems
- Cryoablation for Bone Metastases: Pain Control and Local Treatment
Frequently Asked Questions
Common questions from patients with bone metastasis pain considering HIFU.
About HIFU for Bone Pain
How long does the pain relief from MRgFUS bone treatment last?
The majority of responders experience sustained pain relief for 3–6 months. In some patients — particularly those with good local tumour control — relief persists beyond 12 months. If pain returns due to local tumour regrowth or new lesions at adjacent sites, MRgFUS can be repeated at the same site (there is no cumulative dose limit) or used to treat new painful lesions independently. The absence of a radiation dose ceiling is one of MRgFUS's most practically important advantages for patients with progressive bone metastatic disease.
Is MRgFUS bone treatment available in China?
Yes — ExAblate and equivalent MRgFUS systems are installed at several major Chinese cancer centres including CAMS Cancer Hospital, Sun Yat-sen University Cancer Center, and affiliated institutions. USgHIFU (HAIFU system) is more widely available across China and can also treat accessible bone metastases — though without the MR thermometry advantage for spinal lesions. CancerFax can identify which centre has the most appropriate system for your specific bone metastasis site and prior treatment history.
Can HIFU be used while I am on bone-modifying agents like denosumab or zoledronic acid?
Yes — bisphosphonates and denosumab are continued without modification around MRgFUS bone procedures. These agents do not affect the acoustic properties of bone or the thermal ablation mechanism. Some centres prefer to avoid MRgFUS within 48 hours of an intravenous bisphosphonate infusion due to the transient post-infusion systemic inflammatory response, but this is a precautionary scheduling preference rather than a clinical contraindication. Confirm the timing with your treating team when planning the procedure date.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Could MRgFUS Relieve Your Bone Metastasis Pain?
CancerFax reviews your imaging and bone metastasis pain profile to assess whether MRgFUS or USgHIFU bone treatment is appropriate — and connects you with specialist centres in China and India with the system suited to your lesion location and prior treatment history.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.